Tumor profiling of gastric and esophageal carcinoma reveal different treatment options

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; http://dx.doi.org/10.1002/ijc.25516
   PubMed Web of Science ®Google Scholar
• Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11-20; PMID:16822992; http://dx.doi.org/10.1056/NEJMoa055531
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Gastric Cancer (Including cancer in the proximal 5cm of the stomach).
   Google Scholar
• National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers.
   Google Scholar
• Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687-97; PMID:20728210; http://dx.doi.org/10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, Zhao Z, Xu Z, El-Rifai W. Gastric adenocarcinoma has a unique microRNA signature not present in esophageal adenocarcinoma. Cancer 2013; 119:1985-93; PMID:23456798; http://dx.doi.org/10.1002/cncr.28002
   PubMed Web of Science ®Google Scholar
• Boland P, Burtness B. Esophageal carcinoma: are modern targeted therapies shaking the rock? Curr Opin Oncol 2013; 25:417-24; PMID:23680713; http://dx.doi.org/10.1097/CCO.0b013e328362105e
   PubMed Web of Science ®Google Scholar
• Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC. Molecular profiling in gastric cancer: examining potential targets for chemotherapy. J Surg Oncol 2014; 110:302-6; PMID:24844210; http://dx.doi.org/10.1002/jso.23639
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Stephenson JJ Jr., Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28:4877-82; PMID:20921468; http://dx.doi.org/10.1200/JCO.2009.26.5983
   PubMed Web of Science ®Google Scholar
• Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19:1523-9; PMID:18441328; http://dx.doi.org/10.1093/annonc/mdn169
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16:273-8; PMID:15668283; http://dx.doi.org/10.1093/annonc/mdi064
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903-9; PMID:16782930; http://dx.doi.org/10.1200/JCO.2005.05.0245
   PubMed Web of Science ®Google Scholar
• Palacio S, Loaiza-Bonilla A, Kittaneh M, Kyriakopoulos C, Ochoa RE, Escobar M, Arango B, Restrepo MH, Merchan JR, Rocha Lima CM, et al. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer. Anticancer Res 2014; 34:301-6; PMID:24403478
   PubMed Web of Science ®Google Scholar
• Christman K, Kelsen D, Saltz L, Tarassoff PG. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994; 73:5-7; PMID:8275437; http://dx.doi.org/10.1002/1097-0142(19940101)73:1%3c5::AID-CNCR2820730103%3e3.0.CO;2-
   PubMed Web of Science ®Google Scholar
• De Lange SM, van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF, Peters GJ, Pinedo HM, Giaccone G. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 2004; 15:484-8; PMID:14998853; http://dx.doi.org/10.1093/annonc/mdh109
   PubMed Web of Science ®Google Scholar
• Dong X, Hao Y, Wei Y, Yin Q, Du J, Zhao X. Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression. PLoS One 2014; 9:e92320
   PubMed Web of Science ®Google Scholar
• Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, et al. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 2012; 30:3633-9; PMID:22965953; http://dx.doi.org/10.1200/JCO.2011.40.7783
   PubMed Web of Science ®Google Scholar
• Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, Yamada T, Majumdar D, Kennedy SA, Beattie CW, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer 2013; 108:1061-70; PMID:23449360; http://dx.doi.org/10.1038/bjc.2013.74
   PubMed Web of Science ®Google Scholar
• Lesko AC, Goss KH, Prosperi JR. Exploiting APC function as a novel cancer therapy. Curr Drug Targets 2014; 15:90-102; PMID:24200292; http://dx.doi.org/10.2174/1389450114666131108155418
   PubMed Web of Science ®Google Scholar
• Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V, Smith P, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14:38-47; http://dx.doi.org/10.1016/S1470-2045(12)70489-8
   PubMed Web of Science ®Google Scholar
• Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011; 10:558-65; PMID:21216929; http://dx.doi.org/10.1158/1535-7163.MCT-10-0994
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457:299-307; PMID:20665045; http://dx.doi.org/10.1007/s00428-010-0952-2
   PubMed Web of Science ®Google Scholar